Pharmacokinetics, Safety, and Tolerability of Various XW10172 Oral Formulations in Healthy Adult Volunteers

XWPharma

Status and phase

Completed

Early Phase 1

Conditions

Healthy

Treatments

Drug: XW10172

Study type

Interventional

Funder types

Industry

Identifiers

XW10172-102

Details and patient eligibility

About

The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of various formulations of XW10172 in healthy volunteers.

Enrollment

46 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy male of female participants who are 18 to 55 years of age, inclusive.
Participant is willing and able to provide signed and dated written informed consent to participate prior to admission to the study.

Exclusion criteria

Evidence or history of clinically significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, psychiatric, neurological, immunological, or endocrine disorders, poor vision, or allergic disease including drug allergies, including immediate type hypersensitivity. A history of childhood asthma that has resolved is acceptable.
Participant who, for any reason, is deemed by the investigator to be inappropriate for this study; or has any condition which would confound or interfere with the evaluation of the safety, tolerability, pharmacokinetics or pharmacodynamics of the investigational drug; or is unable to comply with the study protocol.